SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders debating whether guidance, subscriber engagement and ad growth can offset concerns about slowing growth and the content slate. Sentiment leans bearish amid the stocks decline and traders claims of repeated post-earnings selloffs, though some see low expectations as room for a rebound.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound and heavy buying have fueled attention as traders anticipate the 80th-event trigger and final-analysis results for SELLASs Phase 3 REGAL trial of GPS. Some also read the CEOs anniversary remarks and planned ASH presence as possible buyout signals, but others stress there is no confirmed deal or trial result and that the price move may be trading activity.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly earnings and forward guidance are the dominant focus, particularly whether AI and data-center revenue can justify heavy capital spending. Traders are split between expecting a profitable report and rally and worrying about debt, spending, valuation, and an upcoming share unlock.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets reported Willow quantum-computing advanceusing magic state cultivation to cut errors roughly 40-foldhas sparked interest, though traders question whether it will matter to the stock near term as the share price remains weak. Conversation also centers on the upcoming earnings report and whether the recent pullback is a buying opportunity or reflects broader tech and AI-spending concerns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs rise is being linked by traders both to strength across biotech and to the reported Silence Therapeutics acquisition, which some see as a sign of pharma interest in siRNA therapies relevant to Sareptas pipeline. Others view the move as a sector-driven bounce or short covering, and say upcoming DM1 and FSHD datanot a confirmed Sarepta-specific announcementwill be key.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas potential Monee fintech listing and launch of its Sea Cloud AI venture are fueling debate as shares sell off: some traders see a possible Monee separation and cloud investment as sources of uncertainty, while others argue the moves could unlock value and expand growth. The decline has intensified bearish technical commentary and speculation about insider selling, alongside bullish claims that the reaction is an overreaction.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are the main focus, with traders watching Google Cloud and Gemini for signs of growth. The discussion is divided between optimism about AI and cloud momentum and concern that heavy AI spending, alongside recent share-price weakness, could weigh on returns.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is drawing attention as traders position around the detailed Phase 3 results for its personalized melanoma cancer vaccine with Merck at ESMO, following a positive topline readout. Bulls see the data as validation of its oncology platform, while skeptics warn that the sharp rally may have priced in strong results and could reverse on a sell-the-news reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are falling despite a third-quarter earnings and revenue beat and a new buyback authorization, as investors focus on a narrowed full-year profit outlook with its midpoint unchanged rather than an upgrade. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and capital returns, and seeing the outlook and softer vehicle sales as reasons for caution.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs steep selloff is drawing attention amid broader funding and return concerns for AI-focused neoclouds, with traders also questioning the companys execution, dilution and delayed Horizon capacity. Co-CEO Daniel Roberts comments that data-center construction has been cash-funded and customer prepayments help finance GPUs are cited by bulls, but have not eased the bearish debate or frustration that IREN is lagging peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders

(RTTNews) - On Wednesday, Pharming Group N.V. (PHAR) announced positive topline results from a Phase II study evaluating Leniolisib in patients with genetically identifiable primary immunodeficiencies (PIDs) associated with immune dysregulation linked to altered PI3Kdelta signa...

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Pharming Gets FDA Approval For Joenja In Children With APDS

(RTTNews) - Pharming Group N.V. (PHARM.AS) said the U.S. Food and Drug Administration has approved Joenja (leniolisib) for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome, or APDS, who weigh at least 27 kg...

Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky

Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 7, 2026 Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375...

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) investors concerning the Companys possible violations of the federal securities laws...

Pharming Group N.V. (PHAR) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PHARMING GROUP N.V. (PHAR), CONTACT THE...

Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (Pharming or the Company) (NASDAQ: PHAR) on behalf of investors concerning the Companys possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHARMING GROUP N.V. (PHAR), CLICK HERE...

PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group

PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group PHAR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Pharming Group PR Newswire NEW YORK, Aug. 3, 2026 On May 7, 2026, Pharming...

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and three hav...

This account has been verified as an official PHAR representative.

Verified Account

Pharming Group IR

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Pharming Group N.V. - ADR

Neutral Sentiment

<ul class="summary-bullets"><li>TRAX plans to release top-line data from the first ANB033 celiac-disease study cohort on Monday.</li><li>CYTK will present additional Aficamten analyses at HFSA, while EPRX presents previously disclosed EP-104GI data at ACG.</li><li>ARWR and VSTM have clinical updates scheduled for Wednesday on Alzheimer’s research and the cancer drug VS-7375.</li></ul><p>Biotech investors face a packed week, with First Tracks set to report early data on a celiac-disease drug, Verastem preparing an update on a cancer treatment, and the FDA approaching decisions on two eye therapies.</p><p>The&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> gained 2.8% last week, outperforming&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a>, up 1.2%, and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, up 0.2%. The&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> rose 0.6%, trailing SPY but beating QQQ, while the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> fell 0.4%.</p><p><img src="https://news.stocktwits-cdn.com/healthcare_d7c3a475bc.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.12</td><td>TRAX</td><td>First Tracks plans to report Cohort 1 top-line data for ANB033 in celiac disease; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.12</td><td>CYTK / HFSA</td><td>Two late-breaking analyses of Aficamten in nonobstructive hypertrophic cardiomyopathy at the HFSA meeting</td></tr><tr><td>Oct.12</td><td>EPRX / ACG</td><td>Poster on EP-104GI and dysphagia improvements through 52 weeks in the RESOLVE study</td></tr><tr><td>Oct.13</td><td>JNJ</td><td>Third-quarter results; investor call at 8:30 a.m. ET</td></tr><tr><td>Oct.14</td><td>ARWR</td><td>Webinar with interim clinical data from the ARO-MAPT study in Alzheimer’s disease and other tauopathies</td></tr><tr><td>Oct.14</td><td>VSTM</td><td>Investor event with initial efficacy and updated safety data for VS-7375</td></tr><tr><td>Oct.14-Oct.17</td><td>PHAR / ESID</td><td>Late-breaking presentation of Phase 2 Leniolisib data in primary immunodeficiencies with immune dysregulation</td></tr><tr><td>Oct.15</td><td>RHHBY</td><td>FDA target action date for Roche’s Enspryng in thyroid eye disease</td></tr><tr><td>Oct.17</td><td>VTRS / IRD</td><td>FDA target action date for phentolamine ophthalmic solution 0.75% in presbyopia</td></tr><tr><td>Oct.17-Oct.20</td><td>UEG Week</td><td>Gastroenterology conference in Barcelona, with presentations from EPRX, ABVX, Agomab and PALI</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Monday: TRAX, CYTK and EPRX</strong></h2><p>First Tracks Biotherapeutics plans to report top-line data on Monday from Cohort 1 of its Phase 1b study of ANB033, a drug that blocks the immune target CD122. The gluten-challenge study is testing whether the drug can protect the intestinal lining from damage in people with celiac disease.&nbsp;</p><p>Cytokinetics (CYTK) will present two late-breaking analyses of Aficamten on Monday at the Heart Failure Society of America’s meeting in Phoenix. The ACACIA-HCM analyses examine the drug’s overall effectiveness and impact on exercise performance in nonobstructive hypertrophic cardiomyopathy, where a thickened heart muscle does not block blood flow. The company plans to submit a supplemental new drug application in the fourth quarter.&nbsp;</p><p>Eupraxia Pharmaceuticals (EPRX) will present a poster on Monday at the American College of Gastroenterology meeting on EP-104GI in eosinophilic esophagitis, an inflammatory condition of the esophagus. It will examine improvements in difficulty swallowing that lasted up to 52 weeks in the Phase 1b/2 Resolve study. Eupraxia reported the 52-week results from its highest-dose group late last month.&nbsp;</p><h2 class="st-heading-2"><strong>Midweek: JNJ, ARWR And VSTM</strong></h2><p>Johnson &amp; Johnson (JNJ) will report its third-quarter results on Tuesday. According to Koyfin, analysts expect revenue of $25.38 billion, up 0.3%. They forecast earnings before interest, taxes, depreciation and amortization (EBITDA) at $8.24 billion, down 8%, and earnings before interest and taxes (EBIT) at $7.42 billion, down 10%. GAAP earnings per share (EPS) are projected at $2.07, down 9%.</p><p>On Wednesday, Arrowhead Pharmaceuticals (ARWR) will share interim results from an early-stage study of ARO-MAPT, its treatment for Alzheimer’s disease and other disorders linked to abnormal tau protein. A webinar on the same day will also include an update on the company’s central nervous system pipeline.</p><p>Verastem Oncology (VSTM) will host an investor event on Wednesday to present initial efficacy results and updated safety data for VS-7375. The oral drug targets KRAS G12D, a cancer-driving mutation, and is being studied in pancreatic, lung and colorectal cancers as part of the Target-D program.</p><h2 class="st-heading-2"><strong>FDA Target Dates Loom For 2 Eye Treatments</strong></h2><p>Roche (RHHBY) is awaiting an FDA decision by Thursday on its application to use Enspryng (Satralizumab) to treat thyroid eye disease. The application received Priority Review. If approved, Roche says Enspryng could become the first at-home, under-the-skin treatment for the condition. The Phase 3 SatraGO results were presented last year.</p><p>Viatris (VTRS) and Opus Genetics (IRD) face an Oct.17 FDA target date for phentolamine eye drops, also known as MR-141, as a treatment for presbyopia — the age-related difficulty focusing on nearby objects. The FDA accepted the application seeking approval for this new use.</p><h2 class="st-heading-2"><strong>GI Conferences Bring More Data Presentations</strong></h2><p>Pharming (PHAR) will present previously announced Phase 2 results for Leniolisib at the European Society for Immunodeficiencies meeting, running Oct.14-Oct.17 in the Netherlands. The study involved patients with rare, genetically defined immune disorders. Pharming released the top-line findings last month.&nbsp;</p><p>Meanwhile, the United European Gastroenterology Week runs from Oct.17-Oct.20 in Barcelona. Abivax (ABVX) will present seven Obefazimod abstracts, including results from a Phase 3 maintenance study and patient subgroup analyses, longer-term Phase 2 findings and a preclinical study.</p><p>Agomab will present long-term data from an extension of its STENOVA Phase 2a study, in which patients continued Ontunisertib treatment for up to 60 weeks. The study focuses on fibrostenosing Crohn’s disease, which can cause narrowing of the bowel. Palisade Bio (PALI) will make four presentations on PALI-2108, including Phase 1b findings on early clinical improvements and evidence that the drug affects PDE4, a protein involved in inflammation. Three additional posters will cover gut-targeted delivery, safety and potential biomarkers that could help predict treatment response.</p><p>Separately, Filana Therapeutics (FLNA) said it will attend the Maxim Growth Summit, running Oct.12-Oct.14, for one-on-one meetings.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-retail-big-pharma-buyout-booth-ash/cZx4tMpRBF7">SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&amp;A Negotiation Lounge' Booth At ASH&nbsp;</a></p>

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Abivax - ADR

Arrowhead Pharmaceuticals Inc.

Cytokinetics Inc

Eupraxia Pharmaceuticals Inc

Filana Therapeutics Inc

iShares Biotechnology ETF

Opus Genetics Inc.

Johnson & Johnson

Palisade Bio Inc

Pharming Group

Roche Holdings AG ADR

First Tracks Biotherapeutics Inc.

Verastem Inc

Viatris Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.62
Prev Close	$9.11
Open	$9.39
Dividend Yield	0.00%
50-Day Moving Average	$10.81
Beta	0.63
Avg. Volume	36,068.13
PE Ratio	68.81

52-Week High	$21.34
52-Week Low	$9.11
Market Capitalization	$644.79M
EPS (Annual)	$0.0415
Price to Book	2.51
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

PHAR Fundamentals